Top-Rated StocksTop-RatedNASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis → Musk’s new company could top a trillion? (From Paradigm Press) (Ad) Free RGEN Stock Alerts $123.39 -0.96 (-0.77%) (As of 03:39 PM ET) Add Compare Share Share Today's Range$121.16▼$125.2950-Day Range$124.35▼$181.9252-Week Range$110.45▼$211.13Volume716,017 shsAverage Volume561,033 shsMarket Capitalization$6.90 billionP/E Ratio493.58Dividend YieldN/APrice Target$197.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Repligen alerts: Email Address Repligen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside60.8% Upside$197.75 Price TargetShort InterestBearish8.33% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment1.24Based on 15 Articles This WeekInsider TradingSelling Shares$3.38 M Sold Last QuarterProj. Earnings Growth39.04%From $1.46 to $2.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.64 out of 5 starsMedical Sector73rd out of 913 stocksBiological Products, Except Diagnostic Industry8th out of 152 stocks 3.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has only been the subject of 2 research reports in the past 90 days.Read more about Repligen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.33% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Repligen has recently decreased by 0.46%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 3.5 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Repligen this week, compared to 5 articles on an average week.Search Interest2 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold 650.62% more of their company's stock than they have bought. Specifically, they have bought $449,938.00 in company stock and sold $3,377,315.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 39.04% in the coming year, from $1.46 to $2.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 491.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 135.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 491.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 137.80.Price to Earnings Growth RatioRepligen has a PEG Ratio of 4.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Repligen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Repligen Stock (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesJune 15 at 9:50 AM | insidertrades.comRepligen Co. (NASDAQ:RGEN) Director Buys $201,778.10 in StockJune 15 at 8:49 AM | insidertrades.comInsider Buying: Repligen Co. (NASDAQ:RGEN) CEO Purchases 2,000 Shares of StockJune 18, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 24, 2024 | insidertrades.comRepligen Co. (NASDAQ:RGEN) CEO Sells $3,377,314.72 in StockJune 18 at 8:18 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Receives New Coverage from Analysts at GuggenheimJune 16 at 5:26 AM | americanbankingnews.comAnthony Hunt Purchases 2,000 Shares of Repligen Co. (NASDAQ:RGEN) StockJune 16 at 3:10 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Sees Large Volume Increase Following Insider Buying ActivityJune 13, 2024 | globenewswire.comRepligen Announces CEO Transition PlanJune 18, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 30, 2024 | seekingalpha.comRepligen Stock: Still Quite OvervaluedMay 23, 2024 | finance.yahoo.comInsider Sell: CEO Anthony Hunt Sells 20,072 Shares of Repligen Corp (RGEN)May 22, 2024 | globenewswire.comRepligen Corporation to Present at Upcoming June Investor ConferencesMay 15, 2024 | msn.comHere's Why Baron Discovery Fund Sold Repligen Corporation (RGEN)May 15, 2024 | finance.yahoo.comHere’s Why Baron Discovery Fund Sold Repligen Corporation (RGEN)May 10, 2024 | finance.yahoo.comWe Discuss Why Repligen Corporation's (NASDAQ:RGEN) CEO Compensation May Be Closely ReviewedMay 7, 2024 | globenewswire.comRepligen Corporation to Present at Upcoming May Investor ConferencesMay 3, 2024 | finance.yahoo.comRepligen First Quarter 2024 Earnings: EPS Misses ExpectationsMay 2, 2024 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...May 2, 2024 | gurufocus.comQ1 2024 Repligen Corp Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst ProjectionsMay 1, 2024 | investorplace.comRGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | msn.comRepligen reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | globenewswire.comRepligen Reports First Quarter 2024 Financial ResultsApril 29, 2024 | nasdaq.comRGEN Quantitative Stock AnalysisApril 23, 2024 | finance.yahoo.comShould be Confident in Repligen Corporation (RGEN)’s Long-Term Growth Potential?April 19, 2024 | markets.businessinsider.comPositive Report for Repligen (RGEN) from Craig-HallumSee More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/18/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$197.75 High Stock Price Target$220.00 Low Stock Price Target$170.00 Potential Upside/Downside+59.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.25 Trailing P/E Ratio496.54 Forward P/E Ratio85.02 P/E Growth4.19Net Income$41.58 million Net Margins2.44% Pretax Margin4.96% Return on Equity3.95% Return on Assets2.90% Debt Debt-to-Equity Ratio0.26 Current Ratio6.35 Quick Ratio5.24 Sales & Book Value Annual Sales$638.76 million Price / Sales10.86 Cash Flow$2.99 per share Price / Cash Flow41.52 Book Value$35.31 per share Price / Book3.52Miscellaneous Outstanding Shares55,880,000Free Float55,205,000Market Cap$6.94 billion OptionableOptionable Beta1.04 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 60)CEO & Director Comp: $885kMr. Olivier Loeillot (Age 54)President & Chief Commercial Officer Comp: $1.49MMr. Jason K. Garland (Age 50)CFO & Chief Compliance Officer Comp: $282.99kMr. James R. Bylund (Age 60)Chief Operating Officer Comp: $472.18kMs. Christine Gebski (Age 56)Senior Vice President of Filtration & Chromatography Comp: $396.09kMr. Ralf Kuriyel (Age 66)Senior Vice President of Research & Development Comp: $401.74kMr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGeneral Counsel & Global Head of LegalDr. Jaime M. Humara Ph.D.Senior Vice President of Global MarketingMore ExecutivesKey CompetitorsQiagenNYSE:QGENCRISPR TherapeuticsNASDAQ:CRSPAcceleron PharmaNASDAQ:XLRNBio-TechneNASDAQ:TECHDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsAnthony HuntBought 2,000 shares on 6/14/2024Total: $248,160.00 ($124.08/share)Martin D MadausBought 1,615 shares on 6/14/2024Total: $201,778.10 ($124.94/share)NBW Capital LLCBought 578 shares on 6/13/2024Ownership: 0.060%DekaBank Deutsche GirozentraleSold 284 shares on 6/4/2024Ownership: 0.014%Anthony HuntSold 20,072 sharesTotal: $3.38 M ($168.26/share)View All Insider TransactionsView All Institutional Transactions RGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Repligen stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price target for 2024? 10 analysts have issued twelve-month price targets for Repligen's shares. Their RGEN share price targets range from $170.00 to $220.00. On average, they expect the company's share price to reach $197.75 in the next year. This suggests a possible upside of 60.8% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2024? Repligen's stock was trading at $179.80 at the start of the year. Since then, RGEN stock has decreased by 31.6% and is now trading at $122.96. View the best growth stocks for 2024 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its earnings results on Wednesday, May, 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by $0.01. The biotechnology company earned $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a trailing twelve-month return on equity of 3.95%. Repligen's quarterly revenue was down 17.1% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), BlackRock Future Innovators ETF (BFTR), Invesco Biotechnology & Genome ETF (PBE), BNY Mellon Innovators ETF (BKIV), Congress SMid Growth ETF (CSMD), Fidelity Disruptive Medicine ETF (FMED), Nuveen ESG Mid-Cap Growth ETF (NUMG) and VanEck Biotech ETF (BBH). What guidance has Repligen issued on next quarter's earnings? Repligen updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of 1.420-1.490 for the period, compared to the consensus earnings per share estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). Who are Repligen's major shareholders? Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.13%), Price T Rowe Associates Inc. MD (6.39%), Brown Capital Management LLC (2.07%), Bank of New York Mellon Corp (2.03%), Conestoga Capital Advisors LLC (1.34%) and William Blair Investment Management LLC (1.14%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More This page (NASDAQ:RGEN) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.